IMVT
Price
$29.47
Change
-$1.00 (-3.28%)
Updated
Oct 12, 04:59 PM (EDT)
Capitalization
6.92B
37 days until earnings call
Intraday BUY SELL Signals
XNCR
Price
$25.03
Change
+$0.40 (+1.62%)
Updated
Oct 12, 04:59 PM (EDT)
Capitalization
1.9B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMVT vs XNCR

IMVT vs XNCR Comparison Chart in %
View a ticker or compare two or three
VS
IMVT vs. XNCR commentary
Oct 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Hold and XNCR is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
IMVT vs XNCR: Fundamental Ratings
IMVT
XNCR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
58100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
5635
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (51) in the null industry is somewhat better than the same rating for XNCR (88) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than XNCR’s over the last 12 months.

IMVT's Profit vs Risk Rating (58) in the null industry is somewhat better than the same rating for XNCR (100) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than XNCR’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as IMVT (98) in the null industry. This means that XNCR’s stock grew similarly to IMVT’s over the last 12 months.

XNCR's Price Growth Rating (35) in the Biotechnology industry is in the same range as IMVT (56) in the null industry. This means that XNCR’s stock grew similarly to IMVT’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that XNCR’s stock grew significantly faster than IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTXNCR
RSI
ODDS (%)
Bullish Trend 4 days ago
86%
N/A
Stochastic
ODDS (%)
N/A
Bearish Trend 4 days ago
79%
Momentum
ODDS (%)
N/A
Bullish Trend 4 days ago
70%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 21 days ago
77%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
81%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
79%
Aroon
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
84%
COMPARISON
Comparison
Oct 12, 2026
Stock price -- (IMVT: $30.47 vs. XNCR: $24.63)
Brand notoriety: IMVT and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 112% vs. XNCR: 69%
Market capitalization -- IMVT: $6.92B vs. XNCR: $1.9B
IMVT [@Biotechnology] is valued at $6.92B. XNCR’s [@Biotechnology] market capitalization is $1.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 3 TA indicator(s) are bullish while XNCR’s TA Score has 2 bullish TA indicator(s).

  • IMVT’s TA Score: 3 bullish, 3 bearish.
  • XNCR’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than XNCR.

Price Growth

IMVT (@Biotechnology) experienced а -9.37% price change this week, while XNCR (@Biotechnology) price change was -0.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.98%. For the same industry, the average monthly price growth was -11.40%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

IMVT is expected to report earnings on Nov 18, 2026.

XNCR is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IMVT
Daily Signal:
Gain/Loss:
XNCR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VSS155.121.51
+0.98%
Vanguard FTSE All-World ex-US Small-Cap ETF (VSS)
LOWV84.750.68
+0.81%
AB US Low Volatility Equity ETF (LOWV)
ERET26.850.17
+0.65%
iShares Environmentally Aware Real Estate ETF (ERET)
YBIT20.320.13
+0.64%
Yieldmax Bitcoin Option Income Strategy ETF
OUSA60.870.07
+0.12%
ALPS O'Shares U.S. Quality Dividend ETF (OUSA)

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+0.69%
ROIV - IMVT
62%
Loosely correlated
+3.60%
KURA - IMVT
53%
Loosely correlated
+0.76%
SYRE - IMVT
46%
Loosely correlated
+7.25%
NRIX - IMVT
45%
Loosely correlated
+0.63%
XNCR - IMVT
43%
Loosely correlated
+0.53%
More